Humanigen Doses First Patient in Acute Graft Versus Host Disease Clinical Trial

Humanigen, Inc. (OTC Pink: HGEN) has successfully dosed the first participant in a clinical trial evaluating lenzilumab for the early treatment of acute Graft versus Host Disease (aGvHD). The company’s share price was up 25% following the news.

Professor Adrian Bloor MA, MB BChir, PhD, FRCP, FRCPath, director of Stem Cell Transplantation, The Christie NHS Foundation Trust, said, “I am delighted that we have treated our first patient and am grateful to the IMPACT Partnership, Humanigen and to the US MAGIC Consortium for supporting this important study.”


The trial will be conducted at approximately 18 sites across the UK. The first stage of the trial will treat around 20 participants with lenzilumab before conducting an interim assessment of safety, efficacy, and feasibility. The second stage of the study is expected to enroll approximately 220 patients.

Mortality from aGvHD is as high as 70%-75% and patients with Grade III aGvHD may not survive more than two years.

Lenzilumab is intended to neutralize the immune signalling of the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which may initiate the inflammatory cascade that drives aGvHD.

Humanigen’s study is conducted by IMPACT, a world-class accelerated clinical trial network delivering innovative research for stem cell transplant patients in major centers in the UK.

About Humanigen

Humanigen, Inc. (OTC Pink: HGEN) (“Humanigen”), is a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor. Humanigen is developing lenzilumab as a treatment for chronic myelomonocytic leukemia and acute graft versus host disease. Humanigen is also exploring use of lenzilumab to prevent toxicities associated with CAR-T therapy through investigator-initiated trials. Humanigen is also developing an antibody drug conjugate (ADC) utilizing its EphA-3 targeted monoclonal antibody ifabotuzumab (“ifab”) for solid tumors. For more information, visit and follow Humanigen on Twitter.

Share This Article


About the Author

Humanigen Doses First Patient in Acute Graft Versus Host Disease Clinical Trial

Editor Prism MarketView